Drug Trial Radar · NCT06751329
A Study of DM002 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
280
Planned (sponsor's estimate)
Start
Feb 17, 2025
Primary completion
Oct 8, 2027
Study completion Apr 18, 2028
Sponsor
- Lead sponsor
- Xadcera Biopharmaceutical (Suzhou) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of study: The study has two parts: Part 1 Dose Escalation and Part 2 Dose Expansion. In Part 1, a few participants will receive the lowest dose of study drug. The study team will make sure it is safe and tolerated before enrolling new participants at a higher dose of study drug. There will be up to six or more dose levels of study drug tested (called cohorts). Which dose you receive will depend on how many participants have taken part in the study before you. The purpose of Part 1 of the study is to evaluate the safety of the study drug at different dose levels, to understand what your body does to the study drug, and to find the best dose of study drug in people who have advanced solid tumor cancers. In Part 2, participants will receive the best dose level that was determined in Part 1 of the study. The purpose of Part 2 of the study is to evaluate the safety of the study drug at the dose level determined in Part 1, to understand what your body does to the study drug, and to see how your cancer responds to the study drug. Participants will: Participants will have 17 or more visits to the study centre. This study has a screening phase of up to 28 days , and a treatment phase with cycles of 21 days each. Participants will also have an End of Treatment (EOT) visit 21 days after the final study drug treatment, and a Follow-up visit 30 days after the EOT visit . Participants will be contacted by telephone every 3 months after the Follow-up visit to check on the wellbeing and record any new anticancer therapy they may have started.
Conditions
- Ovarian Neoplasms
- Prostatic Neoplasms
- Endometrial Neoplasms
- Colorectal Neoplasms
- Solid Carcinoma
- Pancreatic Cancer
Interventions
DM002Drug
An IV infusion of DM002 will be administrated approximately 30-60 min on D1 once Q3W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting Toxicities (DLTs) of DM002Time frame: 12 months
- Maximum tolerated dose (MTD) for DM002Time frame: 12 months
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
University of California San Francisco Cancer Center
San Francisco, California · Recruiting
Carolina BioOncology Institute, LLC
Huntersville, North Carolina · Recruiting
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma · Recruiting
The University of Texas, MD Anderson Cancer Center
Houston, Texas · Recruiting
Scientia Clinical Research
Randwick, New South Wales, Australia · Recruiting
Cancer Care Wollongong
Wollongong, New South Wales, Australia · Recruiting
Southern Oncology Clinical Research Unit
Adelaide, South Australia, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.